Similarly, aberrations in the PI3K/AKT/mTOR pathway are commonly described in aggressive cancers [30] and inhibitors of this pathway can improve outcomes in some patients when combined with paclitaxel [30,31,32]. Here, AKT1 is linked to cancer.